Zizic T M, Sutton J D, Stevens M B
Am J Med. 1986 Nov 28;81(5B):29-35.
In a study of the long-term safety and efficacy of piroxicam (20 mg daily) in the treatment of osteoarthritis, 30 female patients with a mean duration of more than seven years of treatment were evaluated. Despite having had poor or no response with other drug therapies, in the majority of cases in which piroxicam was used half of the patients (15 of 30) reported feeling very good or good at their last visit, 13 said they felt fair, and only two reported feeling poor or very poor in terms of their sense of well-being. The incidence of adverse events was somewhat less than one event per patient year of exposure, and 94 percent of adverse events were mild or moderate. Laboratory measurements of drug safety did not reveal any evidence of renal, hepatic, or hematologic toxicity. It is significant that patients were willing to commit themselves to long-term piroxicam therapy for at least five years after an initial trial and that they preferred to continue taking the drug rather than switch to alternative forms of therapy.
在一项关于吡罗昔康（每日20毫克）治疗骨关节炎的长期安全性和有效性的研究中，对30名平均治疗时间超过7年的女性患者进行了评估。尽管这些患者对其他药物治疗反应不佳或没有反应，但在大多数使用吡罗昔康的病例中，一半的患者（30名中的15名）在最后一次就诊时表示感觉非常好或良好，13名患者表示感觉一般，只有2名患者表示在幸福感方面感觉差或非常差。不良事件的发生率略低于每位患者每年暴露1次，且94%的不良事件为轻度或中度。药物安全性的实验室检测未发现任何肾脏、肝脏或血液学毒性的证据。值得注意的是，患者愿意在初步试验后至少接受五年的长期吡罗昔康治疗，并且他们更愿意继续服用该药物而不是改用其他治疗方式。
